Curriculum Vitae

Professional Experience and Postdoctoral Training

• 2008 – present Group leader at the Rudolf-Boehm-Institute, Medical Faculty, University of Leipzig (Prof. Dr. M. Schaefer)
• 2005 – 2008 Research fellow at the Institute of Pharmacology, Charité, Berlin (Prof. Dr. M. Schaefer)

• 2003 – 2004 Postdoc (“Marie Curie Fellowship”) at GlaxoSmithKline, Harlow, Great Britain

• 1997 – 2002 Graduate Student and postdoc at the Institute of Biophysics, Department of Biology, Universität Osnabrück (Prof. Dr. R. Wagner)

Academic Education

• 2015 Habilitation (Pharmacology and Toxicology), Universität Leipzig

• 2001 Dr. rer. nat. (“summa cum laude”), Universität Osnabrück

• 1997 Diploma in Biology, Universität Osnabrück

Honours, Awards, Scholarships and Other Qualifications

• 2001 Award for an outstanding thesis of the Universitätsgesellschaft Osnabrück

Professional Activities, Memberships

• 2012 – present Member of the Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie

Publications

• Spyra S, Meisner A, Schaefer M, Hill K. COX-2-selective inhibitors celecoxib and deracoxib modulate TRPV3 channels. Br J Pharmacol 174:2696-2705, 2017.

• Beckmann H, Richter J, Hill K, Urban N, Lemoine H, Schaefer M. A benzothiadiazine derivative and methylprednisolone are novel and selective activators of transient receptor potential canonical 5 (TRPC5) channels. Cell Calcium 66: 10-18, doi: 10.1016/j.ceca.2017.05.012, 2017.

• Oehler B, Kistner K, Martin C, Schiller J, Mayer R, Mohammadi M, Sauer RS, Filipovic MR, Nieto FR, Kloka J, Pflücke D, Hill K, Schaefer M, Malcangio M, Reeh PW, Brack A, Blum R, Rittner HL. Inflammatory pain control by blocking oxidized phospholipid-mediated TRP channel activation. Sci Rep 7:5447, 2017.

• Hill K, Fiorito S, Taddeo VA, Schulze A, Leonhardt M, Epifano F, Genovese S. Plumbagin, juglone, and boropinal as novel TRPA1 agonists. J Nat Prod 79:697-703, 2016.

• Richter JM, Schaefer M, Hill K. Clemizole hydrochloride is a novel and potent inhibitor of transient receptor potential channel TRPC5. Mol Pharmacol 86:514-521, 2014.

• Richter JM, Schaefer M, Hill K. Riluzole activates TRPC5 channels independently of PLC activity. Br J Pharmacol 171:158-170, 2014.

• Schulze A, Hartung P, Schaefer M, Hill K. Transient receptor potential ankyrin 1 (TRPA1) channel activation by the thienopyridine-type drugs ticlopidine, clopidogrel, and prasugrel. Cell Calcium 55:200-207, 2014.

• Scholze A, Oehler B, Urban N, Schaefer M, Hill K. Apomorphine is a bimodal modulator of TRPA1 channels. Mol Pharmacol 83:542-551, 2013.

• Oehler B, Scholze A, Schaefer M, Hill K. TRPA1 is functionally expressed in melanoma cells but is not critical for impaired proliferation caused by allyl isothiocyanate or cinnamaldehyde. Naunyn Schmiedebergs Arch Pharmacol 385:555-563, 2012.

• Urban N, Hill K, Wang L, Kuebler WM, Schaefer M. Novel pharmacological TRPC inhibitors block hypoxia-induced vasoconstriction. Cell Calcium 51:194-206, 2012.